Dana-Farber’s Breast Oncology Center/X
Oct 15, 2024, 19:00
The use of TDXd for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer – Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center shared a post on X:
“Check out our newest treatment guideline on the use of trastuzumab deruxtecan (TDXd) for patients with Metastatic, HER2-low and HER2-ultralow Breast Cancer.”
More posts featuring Dana-Farber’s Breast Oncology Center.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 15, 2024, 18:57
Oct 15, 2024, 18:54
Oct 15, 2024, 17:41
Oct 15, 2024, 17:37
Oct 15, 2024, 17:36
Oct 15, 2024, 17:32
Oct 15, 2024, 17:26
Oct 15, 2024, 17:20
Oct 15, 2024, 17:18